L
Laurence Collette
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 281
Citations - 37642
Laurence Collette is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 78, co-authored 276 publications receiving 33811 citations. Previous affiliations of Laurence Collette include VU University Amsterdam & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.
Sandra Collette,Laurence Collette,Tom Budiharto,Jean-Claude Horiot,Philip Poortmans,Henk Struikmans,Walter Van den Bogaert,Alain Fourquet,Jos J. Jager,W.J. Hoogenraad,Rolf-Peter Mueller,John M. Kurtz,D.A.L. Morgan,Jean-Bernard Dubois,Emile Salamon,René O. Mirimanoff,Michel Bolla,Marleen Van der Hulst,C.C. Wárlám-Rodenhuis,Harry Bartelink +19 more
TL;DR: Cox regression models of the time to moderate or severe fibrosis were developed on a random set of 1797 patients with and 1827 patients without a boost, and validated in the remaining set, and Nomograms with these factors are proposed to forecast the long-term risk of moderate orsevere fibrosis.
Journal ArticleDOI
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
Audrey Mauguen,Jean Pierre Pignon,Sarah Burdett,Caroline Domerg,David Fisher,Rebecca Paulus,Samithra S.J. Mandrekar,Chandra P. Belani,Frances A. Shepherd,Tim Eisen,Herbert Pang,Laurence Collette,William T. Sause,Suzanne E. Dahlberg,Jeffrey Crawford,Mary O'Brien,Steven E. Schild,Mahesh K. B. Parmar,Jayne F. Tierney,Cécile Le Péchoux,Stefan Michiels,Stefan Michiels,Stefan Michiels +22 more
TL;DR: A high level of evidence is found that DFS is a valid surrogate endpoint for overall survival in studies of adjuvant chemotherapy involving patients with non-small-cell lung cancers, and PFS in those of chemotherapy and radiotherapy for patients with locally advanced lung cancers.
Journal ArticleDOI
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Conny Vrieling,Laurence Collette,Alain Fourquet,W.J. Hoogenraad,Jean-Claude Horiot,Jos J. Jager,S. Bing Oei,Hans Peterse,Marianne Pierart,P. Poortmans,H. Struikmans,W. Van den Bogaert,Harry Bartelink +12 more
TL;DR: It appears that age itself and the boost dose were the only factors that were independently related to local control that might explain the high local recurrence rate in the younger patients.
Journal ArticleDOI
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
Michel Bolla,Philippe Maingon,Christian Carrie,Salvador Villà,P. Kitsios,Philip Poortmans,Santhanam Sundar,Elzbieta van der Steen-Banasik,John Armstrong,Jean-François Bosset,Fernanda G. Herrera,Bradley R. Pieters,Annerie Slot,Amit Bahl,Rahamim Ben-Yosef,Dirk Boehmer,Christopher D Scrase,Laurette Renard,Emad Shash,Emad Shash,Corneel Coens,Alphonsus C.M. van den Bergh,Laurence Collette +22 more
TL;DR: Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
Journal ArticleDOI
The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer
Marcel den Dulk,Hein Putter,Laurence Collette,Corrie A.M. Marijnen,Joakim Folkesson,Jean-François Bosset,Claus Rödel,Krzysztof Bujko,Lars Påhlman,Cornelis J.H. van de Velde +9 more
TL;DR: The results suggest that the APR procedure itself is a significant predictor for non-radical resections and increased risk of LR and death due to cancer for patients with advanced rectal cancer.